Hybio Submits Paragraph IV Challenge For Its Generic Tirzepatide Pen
The ranks of generic rivals to Mounjaro and Zepbound are filling up, with Hybio Pharmaceutical, Adalvo and Amneal announcing their successful submissions.
Generics Bulletin - July 1, 2026

Top Medtechs’ Annual Average Growth Hits 8.5%
A handful of ranking changes among medtech’s topmost global tier in an industry showing healthy growth were reflected in In Vivo’s US dollar-rankings for calendar 2025.
Medtech Insight - July 1, 2026

Ipsen Spending Spree Continues With €700m Memo Buy
The French drugmaker expands its rare disease portfolio to include the Swiss biotech's post-transplant infection therapy potravitug in an area with no approved treatments.
Scrip - July 1, 2026

Zimmer Biomet Adds Non-Opioid Pain Device With Iovera Acquisition
Zimmer Biomet is acquiring Pacira's iovera cryoneurolysis platform for up to $140m, adding a drug-free nerve-blocking device to its orthopedic portfolio.
Medtech Insight - July 1, 2026

Orion Partners With Shilpa On Opdivo Biosimilar In Europe
Orion Pharma and Shilpa Biologicals build on their existing partnership with a fresh nivolumab biosimilar deal.
Generics Bulletin - July 1, 2026

How Neurology M&A Has Evolved Over The Last Decade: Upfronts, Multiples And Mechanisms
An analysis of 75 disclosed acquisitions in the neurology sector totaling over $180bn reveals widening deal values, structurally shifting indication preferences, compressing return multiples, and a new dataset linking acquisition stage and price to post-acquisition clinical outcomes.
In Vivo - July 1, 2026

‘We Don’t See Coherence In This Strategy’ – Medicines for Europe Leaders On The EU Biotech Act
At Medicines for Europe’s legal affairs conference, the mood was broadly receptive to the revised EU pharma package – but far frostier towards the EU Biotech Act’s proposed 12-month SPC extension. Sergio Napolitano and Adrian van den Hoven explained why the latter proposal must be removed.
Generics Bulletin - July 1, 2026

Viatris Eyes First IgAN-Specific Budesonide Therapy In Japan
Viatris’ partnered targeted-release budesonide has hit the primary endpoint in a 39-patient Japanese Phase III IgAN study, setting up a planned NDA submission by the end of 2026.
Generics Bulletin - July 1, 2026

Canada’s Generic GLP-1 Momentum Spreads To Weight Loss
Apotex’s Sevmia approval gives Canada its first generic Wegovy rival, widening the country’s early lead in off-patent semaglutide as more GLP-1 filings await Health Canada decisions.
Generics Bulletin - July 1, 2026

Taking The Temperature On Industry’s Sustainability Progress While The World Heats Up
As the public cools on net zero, the consumer health industry is focusing on helping consumers deal with the effects of climate change. Meanwhile, work continues on the tricky problem of Scope 3 emissions.
HBW Insight - July 1, 2026

LigaChem Attracts Big Investment From Korea National Growth Fund
LigaChem secures hefty new financing from South Korea's National Growth Fund, marking the first domestic bioventure to benefit from the broad economic initiative.
Scrip - July 1, 2026

What’s Next? Five Things To Look Out For In July
Generics Bulletin previews the most noteworthy and anticipated events for July 2026.
Generics Bulletin - July 1, 2026

L’Oréal Bets On Innovist To Finally Break Through In India
L'Oréal has struggled for years to build meaningful market share in India. Can its acquisition of digital-first, ingredient-led Innovist give L'Oréal the consumer resonance and local expertise it needs to make the world’s most populous market its new growth engine?
HBW Insight - July 1, 2026

Nippon Shinyaku Options New DMD Asset Amid Capricor Legal Spat
An option to Elixirgen's mutation-agnostic mRNA candidate could boost Nippon Shinyaku's DMD pipeline ahead of a patent expiry for one of its other top products.
Scrip - July 1, 2026